{"DataElement":{"publicId":"2183786","version":"1","preferredName":"Recombinant Granulocyte Colony Stimulating Factor Pegfilgrastim Ind-2","preferredDefinition":"the yes/no indicator whether there was administration of a long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF).","longName":"RECOM_GCSF_ADM_IND2","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3534087","version":"1","preferredName":"Recombinant Granulocyte Colony Stimulating Factor Pegfilgrastim Administered","preferredDefinition":"information related to administration of a long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF).","longName":"GCSF_PEG_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2582947","version":"1","preferredName":"Recombinant Granulocyte Colony Stimulating Factor","preferredDefinition":"G-CSF. A colony-stimulating factor that stimulates the production of neutrophils (a type of white blood cell).  It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called filgrastim.","longName":"C1287","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Granulocyte Colony-Stimulating Factor","conceptCode":"C1287","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF).  Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"258399ED-7A5D-2319-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-12-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2006-12-26","modifiedBy":"ONEDATA","dateModified":"2006-12-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3534085","version":"1","preferredName":"Pegfilgrastim Administered","preferredDefinition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04):The act of having given something (e.g., a medication or test).","longName":"C1854:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegfilgrastim","conceptCode":"C1854","definition":"A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5451973-3354-68B6-E040-BB89AD437DE0","latestVersionIndicator":"Yes","beginDate":"2012-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-20","modifiedBy":"ONEDATA","dateModified":"2012-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5451973-3365-68B6-E040-BB89AD437DE0","latestVersionIndicator":"Yes","beginDate":"2012-07-20","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-07-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964931","version":"1","longName":"2014r1: MDS Pre-HSCT Data","context":"NHLBI"}]}],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"},{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"Pegfilgrastim (Neulasta)","type":"Preferred Question Text","description":"Pegfilgrastim (Neulasta)","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Was pegfilgrastim received","url":null,"context":"CTEP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Has it been more than 14 days since the last dose of pegfilgrastim?","url":null,"context":"COG"},{"name":"CRF Text1","type":"Alternate Question Text","description":"Pegfilgrastim","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DACB6F5A-DE40-00A1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-05-19","modifiedBy":"MORENOC","dateModified":"2019-06-05","changeDescription":"Replaced VD Therapy Ind-2 2018279v1 with Value Domain ID # 3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}